These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 22749283)

  • 1. Enamino-oxindole HIV protease inhibitors.
    Eissenstat M; Guerassina T; Gulnik S; Afonina E; Silva AM; Ludtke D; Yokoe H; Yu B; Erickson J
    Bioorg Med Chem Lett; 2012 Aug; 22(15):5078-83. PubMed ID: 22749283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
    Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
    Ghosh AK; Sridhar PR; Leshchenko S; Hussain AK; Li J; Kovalevsky AY; Walters DE; Wedekind JE; Grum-Tokars V; Das D; Koh Y; Maeda K; Gatanaga H; Weber IT; Mitsuya H
    J Med Chem; 2006 Aug; 49(17):5252-61. PubMed ID: 16913714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
    Lefebvre E; Schiffer CA
    AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
    Amano M; Tojo Y; Salcedo-Gómez PM; Campbell JR; Das D; Aoki M; Xu CX; Rao KV; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2013 May; 57(5):2036-46. PubMed ID: 23403426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological and structural evaluations of novel HIV-1 protease inhibitors to combat drug resistance.
    Parai MK; Huggins DJ; Cao H; Nalam MN; Ali A; Schiffer CA; Tidor B; Rana TM
    J Med Chem; 2012 Jul; 55(14):6328-41. PubMed ID: 22708897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disubstituted Bis-THF Moieties as New P2 Ligands in Nonpeptidal HIV-1 Protease Inhibitors (II).
    Hohlfeld K; Wegner JK; Kesteleyn B; Linclau B; Unge J
    J Med Chem; 2015 May; 58(9):4029-38. PubMed ID: 25897791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
    Ghosh AK; Kulkarni S; Anderson DD; Hong L; Baldridge A; Wang YF; Chumanevich AA; Kovalevsky AY; Tojo Y; Amano M; Koh Y; Tang J; Weber IT; Mitsuya H
    J Med Chem; 2009 Dec; 52(23):7689-705. PubMed ID: 19746963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decomposing the energetic impact of drug-resistant mutations: the example of HIV-1 protease-DRV binding.
    Cai Y; Schiffer C
    Methods Mol Biol; 2012; 819():551-60. PubMed ID: 22183557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20.
    Agniswamy J; Louis JM; Shen CH; Yashchuk S; Ghosh AK; Weber IT
    J Med Chem; 2015 Jun; 58(12):5088-95. PubMed ID: 26010498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies.
    Ghosh AK; Gemma S; Takayama J; Baldridge A; Leshchenko-Yashchuk S; Miller HB; Wang YF; Kovalevsky AY; Koh Y; Weber IT; Mitsuya H
    Org Biomol Chem; 2008 Oct; 6(20):3703-13. PubMed ID: 18843400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, Synthesis, Biological Evaluation, and X-ray Studies of HIV-1 Protease Inhibitors with Modified P2' Ligands of Darunavir.
    Ghosh AK; Fyvie WS; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    ChemMedChem; 2017 Dec; 12(23):1942-1952. PubMed ID: 29110408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.
    Amano M; Salcedo-Gómez PM; Zhao R; Yedidi RS; Das D; Bulut H; Delino NS; Sheri VR; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7046-7059. PubMed ID: 27620483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.
    Yan J; Huang N; Li S; Yang LM; Xing W; Zheng YT; Hu Y
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1976-9. PubMed ID: 22306123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
    Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
    J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors.
    Ghosh AK; Chapsal BD; Steffey M; Agniswamy J; Wang YF; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2012 Mar; 22(6):2308-11. PubMed ID: 22364812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The higher barrier of darunavir and tipranavir resistance for HIV-1 protease.
    Wang Y; Liu Z; Brunzelle JS; Kovari IA; Dewdney TG; Reiter SJ; Kovari LC
    Biochem Biophys Res Commun; 2011 Sep; 412(4):737-42. PubMed ID: 21871444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.
    Amano M; Salcedo-Gómez PM; Yedidi RS; Zhao R; Hayashi H; Hasegawa K; Nakamura T; Martyr CD; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Highly Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors against Lopinavir and Darunavir Resistant Viruses from Allophenylnorstatine-Based Peptidomimetics with P2 Tetrahydrofuranylglycine.
    Hidaka K; Kimura T; Sankaranarayanan R; Wang J; McDaniel KF; Kempf DJ; Kameoka M; Adachi M; Kuroki R; Nguyen JT; Hayashi Y; Kiso Y
    J Med Chem; 2018 Jun; 61(12):5138-5153. PubMed ID: 29852069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.
    Dierynck I; Van Marck H; Van Ginderen M; Jonckers TH; Nalam MN; Schiffer CA; Raoof A; Kraus G; Picchio G
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5723-31. PubMed ID: 21896904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.